Reading SBC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SBC free→Reading SBC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SBC free→QuarterlyIQ Insights · SBC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 14, 2026, Mike Sayama, an independent director of SBC Medical Group Holdings Incorporated (the “Company”), notified the Company that he would not seek re-election at the Company’s forthcoming 2026 Annual Meeting of Stockholders (the “2026 AGM”). The Company’s board of directors has reduced the size of the board of directors to four members,…
Results of Operations and Financial Condition. On May 14, 2026, SBC Medical Group Holdings Incorporated (the “Company”), issued a press release announcing its results for the quarter ended March 31, 2026. The press release is attached as Exhibit 99.1 and is incorporated herein by reference. The information furnished under Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwi…
Entry into a Material Definitive Agreement. On April 19, 2026, SBC Medical Group Holdings Incorporated (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and among the Company, Dr. Yoshiyuki Aikawa, the Company’s CEO and Chairman of the board of directors, as selling stockholder (the “Selling Stockholder”) and Maxim Group LLC, as representative of the several underwriters named in Schedule 1 thereto (the “Underwriters”), relating to an underwritten offeri…
Results of Operations and Financial Condition. On March 27, 2026, SBC Medical Group Holdings Incorporated (the “Company”), issued a press release announcing its fourth quarter and full year 2025 financial results. The press release is attached as Exhibit 99.1 and is incorporated herein by reference. The information furnished under Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), o…
Other Events. On January 5, 2026, the Company announced the completion of a strategic minority equity investment in OrangeTwist, a U.S.-based MedSpa chain, and entered into a structured collaboration framework with OrangeTwist and its institutional shareholders, Hildred Capital and Athyrium Capital (collectively, the “Transaction”). The Transaction marks the Company’s formal entry into the U.S. medical aesthetics market and represents an initial step in the Company’s multi-phase global expans…
Other Events. The Company’s Board of Directors has authorized a $20.0 million share repurchase program, pursuant to which the Company may repurchase shares of its common stock from time to time through open market transactions (including through the use of trading plans intended to qualify pursuant to Rule 10b5-1 under the Exchange Act), through privately negotiated transactions, or by other means, in accordance with applicable securities laws and restrictions. Open market purchases are expec…
Regulation FD Disclosure. On December 31, 2025, SBC Medical Group Holdings Incorporated (the “Company”) issued a press release announcing an updated capital strategy, including the effectiveness of its registration statement on Form S-3 and a $20.0 million share repurchase program, as described under
Results of Operations and Financial Condition. On November 14, 2025, SBC Medical Group Holdings Incorporated (the “Company”), issued a press release announcing its results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated herein by reference. Additionally, on November 13, 2025, the Company posted an investor presentation to its website ( https://sbc-holdings.com/en/ir/ir-presentation ), regarding results for the quarter ended September…
Other Events. On November 13, 2025, the Board of Directors of SBC Medical Group Co., Ltd. (“SBCMG”), a wholly owned subsidiary of SBC Medical Group Holdings Incorporated (the “Company”), approved the commencement of a tender offer (the “Tender Offer”) for shares of the common stock of Waqoo, Inc. (“Waqoo”), a Japanese corporation listed on the Tokyo Stock Exchange Growth Market. As of the date of this report, SBCMG owns 353,600 shares of Waqoo, representing approximately 9.49% of Waqoo’s outs…
Results of Operations and Financial Condition. On August 13, 2025, SBC Medical Group Holdings Incorporated (the “Company”), issued a press release announcing its results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated herein by reference. Additionally, on August 13, 2025, the Company posted an investor presentation to its website ( https://sbc-holdings.com/en/ir/ir-presentation ), regarding results for the quarter ended June 30, 2025 whic…
Regulation FD Disclosure. On July 17, 2025, SBC Medical Group Holdings Incorporated (“SBC Medical”) issued a press release announcing that it has acquired MB career lounge, Co., Ltd., a privately-held provider of management support services for medical institutions, specializing in consulting, training, and human resources solutions in Japan, through a share purchase transaction for cash consideration. The press release is attached as Exhibit 99.1 and is incorporated herein by reference. The…
Results of Operations and Financial Condition. On May 15, 2025, SBC Medical Group Holdings Incorporated, or the Company, issued a press release announcing its results for the quarter ended March 31, 2025. The press release is attached as Exhibit 99.1 and is incorporated herein by reference. Attached hereto as Exhibit 99.2 and incorporated by reference herein is an investor presentation regarding results for the quarter ended March 31, 2025, or the Investor Presentation. The Investor Presentat…
Regulation FD Disclosure On May 15, 2025, the Company issued a press release announcing that its Board of Directors has approved the following share repurchase program and will commence repurchasing its own shares as early as May 20, 2025. Share Repurchase Program ● Maximum aggregate amount : US$5 million ● Implementation period : May 20, 2025 – May 20, 2026 ● Funding source : Surplus cash and future free cash flow. Furthermore, the Company announced in the same press release that it has begu…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 27, 2025, the Board of Directors of SBC Medical Group Holdings Incorporated (the “Company”) approved the following management update: effective April 10, 2025, Miki Shimizu will assume the role of Chief Strategy Officer of the Company, a position currently held by Akira Komatsu. As of such transition date, Mr. Komatsu will hold the positio…
Results of Operations and Financial Condition. On March 28, 2025, SBC Medical Group Holdings Incorporated, or the Company, issued a press release announcing its results for the quarter ended December 31, 2024 and the full year 2024. The press release is attached as Exhibit 99.1 and is incorporated herein by reference. Attached hereto as Exhibit 99.2 and incorporated by reference herein is an investor presentation regarding results for the quarter ended December 31, 2024 and the full year 2024…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.